Mohammed Khawaji1, Jan Astermark, Erik Berntorp. 1. Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö Department of Clinical Sciences, Lund University, Malmö, Sweden. mohammed.khawaji@med.lu.se
Abstract
BACKGROUND: In the 1950s, Sweden initiated prophylaxis as a lifelong treatment for haemophilia. It was the first country to do so. OBJECTIVES: To describe and evaluate dosing and outcome of prophylactic treatment in a large cohort of adult people with severe haemophilia who have been using prophylaxis most of their lives. METHODS: Eighty-one patients born between 1932 and1992 were divided into two groups (Group A started prophylaxis at the age of ≤ 3 yr; Group B at three or more years of age) and evaluated retrospectively. Outcome was evaluated using the Hemophilia Joint Health Score (HJHS) and SF-36, a measure of quality of life. RESULTS: The median number of joint bleeds per year was 0 in both study groups; however, the annual number of joint bleeds during the final 3 yr of observation was higher in group B than in group A (P < 0.006). Twenty-five of 30 patients in group A and 27/51 patients in group B had no joint bleeds in that period. Group A had significantly better joint outcomes than group B. Patients in group A experienced better physical and social health than those in group B. CONCLUSIONS: This follow-up has provided for the first time more extensive and detailed information regarding the practice of prophylactic treatment in a large cohort of adults with severe haemophilia. The present study confirms that early start of prophylaxis continuing throughout the lifespan has been successful in virtually eliminating joint bleeds, preserving a close to normal joint status, and keeping patients healthy and able to live normal lives.
BACKGROUND: In the 1950s, Sweden initiated prophylaxis as a lifelong treatment for haemophilia. It was the first country to do so. OBJECTIVES: To describe and evaluate dosing and outcome of prophylactic treatment in a large cohort of adult people with severe haemophilia who have been using prophylaxis most of their lives. METHODS: Eighty-one patients born between 1932 and1992 were divided into two groups (Group A started prophylaxis at the age of ≤ 3 yr; Group B at three or more years of age) and evaluated retrospectively. Outcome was evaluated using the Hemophilia Joint Health Score (HJHS) and SF-36, a measure of quality of life. RESULTS: The median number of joint bleeds per year was 0 in both study groups; however, the annual number of joint bleeds during the final 3 yr of observation was higher in group B than in group A (P < 0.006). Twenty-five of 30 patients in group A and 27/51 patients in group B had no joint bleeds in that period. Group A had significantly better joint outcomes than group B. Patients in group A experienced better physical and social health than those in group B. CONCLUSIONS: This follow-up has provided for the first time more extensive and detailed information regarding the practice of prophylactic treatment in a large cohort of adults with severe haemophilia. The present study confirms that early start of prophylaxis continuing throughout the lifespan has been successful in virtually eliminating joint bleeds, preserving a close to normal joint status, and keeping patients healthy and able to live normal lives.
Authors: Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp Journal: Blood Date: 2013-06-18 Impact factor: 22.113
Authors: Coline Haxaire; Narine Hakobyan; Tania Pannellini; Camila Carballo; David McIlwain; Tak W Mak; Scott Rodeo; Suchitra Acharya; Daniel Li; Jackie Szymonifka; Xiangqian Song; Sébastien Monette; Alok Srivastava; Jane E Salmon; Carl P Blobel Journal: Blood Date: 2018-05-18 Impact factor: 22.113
Authors: Shannon C Jackson; Ming Yang; Leonard Minuk; Michelle Sholzberg; Jean St-Louis; Alfonso Iorio; Robert Card; Man-Chiu Poon Journal: BMC Hematol Date: 2015-02-14
Authors: Christine L Kempton; Michael Wang; Michael Recht; Anne Neff; Amy D Shapiro; Amit Soni; Roshni Kulkarni; Tyler W Buckner; Katharine Batt; Neeraj N Iyer; David L Cooper Journal: Patient Prefer Adherence Date: 2017-09-19 Impact factor: 2.711